Skip to main content

Table 2 Associations between pCR and clinical/pathologic parameters from logistic regression analysis

From: Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

  Variables N pCR Univariate analysis Multivariate analysis
P OR 95% CI P OR 95% CI
Age, years < 50 66 (60.6) 5 (7.6) 0.817 1   0.656 1  
≥50 43 (39.4) 3 (7.0)   0.915 0.207–4.043   1.231 0.266–8.164
Menopausal status Pre 75 (68.8) 5 (6.7)   1     
Post 34 (31.2) 3 (8.8) 0.690 1.355 0.305–6.027    
Clinical stage 2A 10 (9.2) 0 0.997 0.890
2B 36 (33.0) 3 (37.5)       
3A 48 (44.0) 4 (50.0)       
3B,C 15 (13.8) 1 (12.5)       
Tumor size 1 8 (7.3) 0 0.996 1     
2 77 (70.6) 6 (7.8)     
3–4 24 (22) 2 (8.3)     
LN involvement 0 8 (7.3) 0 0.979 1     
1 46 (42.2) 4 (8.7)     
2 45 (41.3) 3 (6.7)     
3 10 (9.2) 1 (10.0)     
ER, Allred score 0–4 18 (16.5) 3 (16.7) 0.114 1     
5–8 91 (83.5) 5 (5.5)   0.291 0.63–1.346    
PR, Allred score 0–4 27 (24.8) 2 (25) 0.988 1     
5–8 82 (75.2) 6 (75)   0.987 0.187–5.205    
Ki67 index, % < 14 54 (49.5) 2 (3.7) 0.168 1     
≥14 55 (50.5) 6 (10.9)   3.184 0.613–16.531    
Molecular subtype Luminal A-like 75 (68.8) 5 (4.2) 0.274 1   0.294 1  
Luminal B-like 34 (31.2) 3 (9.8)   2.509 0.483–13.032   2.570 0.441–14.973
Regimen AC4 or TC 4 (3.7) 1 (25.0) 0.206 1     
AC4T4 105 (96.3) 7 (6.7)   0.214 0.020–2.338    
pSUVmax <  9.55 70 (64.2) 1 (1.4) 0.013 1   0.013 1  
≥ 9.55 39 (35.8) 7 (17.9)   15.094 1.782–127.880   17.452 1.847–164.892
  1. Numbers in parentheses are percentages. Abbreviations: ER Estrogen receptor; PR Progesterone receptor; pSUVmax SUVmax of primary breast tumor, CR Complete response, AC Anthracycline + cyclophosphamide, T Taxane, TC Docetaxel + cyclophosphamide, BCS Breast conserving surgery, OR Odds ratio, CI Confidence interval
\